Imperagen

Investor: PXN Ventures

Imperagen, a Manchester-based techbio company leveraging AI and quantum physics for enzyme engineering, has successfully secured £5 million in a seed funding round. This investment was led by PXN Ventures, with additional participation from existing investors IQ Capital and Northern Gritstone, bringing Imperagen's total funding to £8.5 million.Summary of transaction details:Value: £5,000,000Sector: Healthcare & BiotechAdvisor: Not specifiedKey Entities: Target: Imperagen; Lead Investor: PXN Ventures; Participating Investors: IQ Capital, Northern GritstoneLocation: Manchester, UKNote: This funding round is intended to significantly accelerate Imperagen's research and development efforts, supporting the expansion of its innovative enzyme engineering platform.

Investor: PXN Ventures

Imperagen, a Manchester-based biotech firm that employs AI and quantum physics to enhance enzyme engineering, has successfully concluded a £5 million seed funding round.Summary of transaction details:Value: £5 millionSector: Healthcare & Biotech (Enzyme Engineering, AI-native DeepTech)Advisor: Not disclosedKey Entities: Target: Imperagen; Lead Investor: PXN Ventures; Participating Investors: IQ Capital, Northern GritstoneLocation: Manchester, UK (Target Company)Note: This funding injection will primarily be used to accelerate Imperagen's core R&D platform, scale its wet lab operations, expand its AI team, and bolster its go-to-market function across pharmaceuticals, life sciences, personal care, and sustainable chemical sectors. The investment underscores confidence in AI-driven deep tech solutions for improving industrial processes.

Investor: PXN Ventures

Imperagen, a University of Manchester techbio spin-out, has secured £5m in a seeding fund round to support its growth plans. Summary of transaction details: Value: £5m Sector: DeepTech & AI Advisor: null Key Entities: Imperagen, PXN Ventures Location: Manchester Note: The funds will be used to accelerate the core R&D platform, scale the wet lab operation, and grow the in-house AI team, both human and agentic.